Engineered monoclonal antibodies have been developed to target specific regions of a TAT-C1aB fusion peptide with high precision. Two antibodies recognize the TAT segment while three target the C1aB segment, with a pair biotinylated to boost detection sensitivity. This configuration is employed in a sandwich ELISA format that necessitates one antibody binding each segment, ensuring that only the intact peptide is detected in biological fluids. The method supports pharmacokinetic studies by tracking the distribution, metabolism, and concentration of the neuroprotective peptide in various biological systems.
Description
What makes this technology stand out is its dual-segment approach that delivers precise specificity by confirming the simultaneous presence of both peptide components. The custom sandwich ELISA offers enhanced sensitivity and robust performance in complex samples, reducing the risk of false positives common with less targeted assays. Additionally, the design’s potential adaptability to monitor other TAT-linked therapeutic peptides broadens its application. This unique combination of biochemical engineering and assay design represents a significant advancement in the detailed tracking and analysis of neuroprotective agents.
Applications
- Pharmacokinetic study support
- Therapeutic peptide detection
- ELISA kit development
- Neuroprotective assay monitoring
Advantages
- High specificity through dual antibody targeting ensures detection of only intact fusion proteins.
- Enhanced sensitivity via biotinylated antibodies improves overall assay performance.
- Enables precise pharmacokinetic studies by tracking the distribution and metabolism of neuroprotective peptides.
- Versatile application potential, as the anti-TAT antibodies can be adapted to detect other TAT-linked therapeutic peptides.
IP Status
Research Tool
